Abstract
Arena is developing APD-356, the lead in a series of orally active, small-molecule 5-hydroxytryptamine 2C agonists for the potential treatment of obesity and diabetes. A phase IIb trial was initiated in June 2005, and preliminary results were expected at the end of 2005.
MeSH terms
-
Animals
-
Appetite Depressants / chemistry
-
Appetite Depressants / therapeutic use*
-
Benzazepines / chemistry
-
Benzazepines / therapeutic use*
-
Clinical Trials as Topic
-
Diabetes Mellitus / drug therapy*
-
Diabetes Mellitus / metabolism
-
Drug Industry
-
Humans
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / therapeutic use*
-
Obesity / drug therapy*
-
Obesity / metabolism
-
Serotonin 5-HT2 Receptor Agonists*
-
Structure-Activity Relationship
-
Treatment Outcome
Substances
-
Appetite Depressants
-
Benzazepines
-
Hypoglycemic Agents
-
Serotonin 5-HT2 Receptor Agonists
-
lorcaserin